

# The Evaluation Advisory Committee (EAC) Report

## Quality assessment of the evaluation

Name of Evaluation: COVAX Facility and AMC and COVAX Pillar Delivery Efforts

Year of report: 2025

a) The Evaluation Advisory Committee (EAC) rated this report as;

- Fully met or exceeded Gavi quality standards
- Met Gavi quality standards with only minor shortcomings
- Partially met Gavi quality standards with some shortcomings
- Did not meet Gavi quality standards with major shortcomings

### b) General comments:

#### Strengths:

The evaluation report is credible, well-structured, and provides valuable insights to inform Gavi 6.0 in relation to Pandemic Prevention Preparedness and Response, Global Health Security, strengthening the Alliance partnership. It also continues to inform the recent adoption of the WHO Pandemic Agreement by the World Health Assembly and ongoing work of the interim Medical Countermeasures Network.

Its strengths lie in clear organization, strong contextual background, stakeholder engagement, and detailed annexes that enhance depth and transparency. Embedded country insights also add richness and practical relevance. Additionally, the executive summary is clear; links between findings, conclusions and recommendations are, overall, well supported by triangulated evidence. The methodology is broadly sound, justification for case study selection and transparency in the evidence rating system are clear.

**Shortcoming:** While the report is clearly written and appropriate for the primary target audiences, it is long and sometimes overly descriptive, which may limit accessibility.

#### Observations

This evaluation marks an important milestone in collaborative evaluation practice - the first formally governed joint evaluation involving Gavi, CEPI, WHO, and UNICEF. While WHO and UNICEF have extensive experience with bilateral joint assessments and evaluations, neither had previously participated in an evaluation of this scale and governance structure. By pooling resources and aligning governance, the partners have reduced the reporting burden on countries, leveraged their comparative advantages to strengthen engagement and utility, and demonstrated the value of "evaluating as a partnership." This joint approach builds on the unique global collaboration of COVAX and is consistent with broader initiatives such as the Lusaka Agenda, while also positioning the Alliance to act proactively in the face of tightening financial conditions across the global health ecosystem.